Life Science Leader

Life Science Leader is a key member of the Life Science Connect media group. The goal of Life Science Connect is to create connections and encourage partnerships in the development of pharmaceuticals and medical devices, ultimately working to bring more life-saving and life-enhancing treatments to the market. The Life Science Connect media group includes a variety of industry websites, the monthly magazine Life Science Leader, conferences focused on the pharmaceutical sector, and the Life Science Training Institute.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#2154899

United States

#948224

Health/Biotechnology and Pharmaceuticals

#907

Traffic sources

Monthly visitors

Articles

Amgen's Ian Thompson On Leadership And A Global Mindset

2 weeks ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Riding for the British Cycling team was a foundational experience for Ian Thompson, SVP and general manager of U.S. business operations at Amgen. During a recent conversation about his 16-year tenure at Amgen, and what the future holds for one of biotech’s biggest success stories, Thompson consistently tied his approach to management and business strategy to lessons learned from cycling — uphill and down.
Companies To Watch: Imunon

3 weeks ago | lifescienceleader.com | Ben Comer

Article | March 31, 2025 Source: Life Science Leader By Ben Comer, Chief Editor, Life Science Leader Using targeted therapy to transform the standard of care in advanced ovarian cancer Snapshot With the recent sign-off from the FDA on protocols for a pivotal Phase 3 trial of IMNN-001 in advanced ovarian cancer, Imunon is poised to bring its IL-12 DNA plasmid vector (encased in a nanoparticle delivery system) into late-stage clinical trials.
How To Get Ready For The Talent Migration Between Pharma And Biotech

1 month ago | lifescienceleader.com | David Ford |John Archer

Guest Column | March 25, 2025 By David Ford and John Archer The life sciences industry is on the brink of a significant shift. Over the next few years, a historic patent cliff will reshape Big Pharma's landscape, triggering waves of talent movement between pharmaceutical and biotech companies. The last time the industry faced a similar challenge was in the early 2010s.
Pharma's Guide To Making Health Communications Land Well

1 month ago | lifescienceleader.com

New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must also be credible and...
A Guide To Successful Product Launches For Small And Midsized Biotechs

1 month ago | lifescienceleader.com

Abhijit Naravane, a partner at PA Consulting, outlines strategies to help biopharma operations leaders successfully navigate the complexities of a...
A CEO With A General Counsel's Perspective

1 month ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Should aspiring biopharmaceutical leaders focus on deep specialization and expertise in a singular area, or seek new and variable experiences across different parts of the business, developing a versatile skillset that can plug and play into leadership roles as needed?
FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance

2 months ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Over the last 15 years, biopharmaceutical compliance departments, and chief compliance officers, have been better resourced, with more direct reporting lines to company leadership, than ever before. A big part of that is thanks to the many Corporate Integrity Agreements (CIAs) companies entered into with government agencies in the late 2000s and up through the present (for background, see my 2013 article in Pharmaceutical Executive).
Where Are They Now? Tarsus Pharmaceuticals

2 months ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Then: In the May 2023 issue of Life Science Leader, Bobak Azamian, MD, Ph.D., cofounder and CEO of Tarsus Pharmaceuticals, talked about the company’s formation in 2016, and the decision to focus on the eyelid as a drug target, and on demodex blepharitis — an inflammatory condition caused by an overabundance of demodex mites — as a specific condition to treat.
Day One Bio Aims To Shorten the Time Gap On Cancer Treatments For Kids

2 months ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader One of the biggest incentives for developing new therapies for rare pediatric cancers is the FDA’s rare pediatric disease Priority Review Voucher (PRV) program. If a drug in development meets the criteria for a PRV, the sponsor company, upon FDA approval, receives a PRV that can be redeemed for FDA priority review of a different pipeline product, or can be sold to another company.
The Spark Of Change In Healthcare's 2024 Investment Ecosystem

2 months ago | lifescienceleader.com

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven strategies, have set the...